GlassScriptPhysician profile
Joseph Dalton
NPI 1053938167
$2,867.17
in general payments reported to CMS, 2019-2025
31 companies · $53.78 in 2025
The $53.78 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $676 · 2023: $1,494 · 2024: $643 · 2025: $53.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,191.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $428.53 | 2023-2024 | |
| Lilly USA, LLC | $286.28 | 2022-2024 | Amyvid, Reyvow, Emgality |
| Axsome Therapeutics, INC. | $233.48 | 2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $147.99 | 2022-2024 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $146.31 | 2022-2024 | Rexulti, Vyepti, Abilify Maintena |
| Acadia Pharmaceuticals INC | $142.98 | 2022 | |
| Pfizer INC. | $135.58 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $134.55 | 2023-2024 | Ingrezza, Ongentys |
| Supernus Pharmaceuticals, INC. | $117.20 | 2022-2023 | Qelbree |
| Janssen Pharmaceuticals, INC | $111.57 | 2023-2025 | Spravato, Invega Sustenna |
| Mdd US Operations, LLC | $107.88 | 2022-2024 | Gocovri, Gocovri, Myobloc |
| Corium, LLC | $103.17 | 2023-2024 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $75.54 | 2022 | |
| Impel Pharmaceuticals INC. | $74.97 | 2023 | Trudhesa |
| Tris Pharma INC | $68.75 | 2023-2024 | Dyanavel Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $64.30 | 2023 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $61.94 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $54.86 | 2022-2023 | Rytary |
| Ucb, INC. | $52.51 | 2023-2024 | Briviact |
| Alexion Pharmaceuticals, INC. | $46.57 | 2023-2024 | Ultomiris |
| Amgen INC. | $42.33 | 2022 | |
| Merck Sharp & Dohme LLC | $32.49 | 2022 | |
| Neos Therapeutics, LP | $32.22 | 2022-2024 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $28.26 | 2023 | Trintellix |
| Avanir Pharmaceuticals, INC. | $23.97 | 2022 | |
| Sumitomo Pharma America, INC. | $23.23 | 2023 | Aptiom |
| Argenx US, INC. | $22.90 | 2024 | Vyvgart Hytrulo |
| Idorsia Pharmaceuticals US INC | $18.83 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $18.69 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.36 | 2022 | |
| Averitas Pharma INC. | $13.93 | 2023 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Dalton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.